Black Diamond Therapeutics (BDTX) Total Debt (2018 - 2020)

Black Diamond Therapeutics (BDTX) posted Total Debt of $190000.0 for Q3 2020, up 1166.67% on a QoQ basis from $15000.0 in Q2 2020.

Black Diamond Therapeutics (BDTX) Total Debt (2018 - 2020) Analysis & Trends

Black Diamond Therapeutics' Total Debt history runs 2 years deep, the most recent figure standing at $190000.0 for Q3 2020.

Quarterly Total Debt changed N/A year-over-year to $190000.0 in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $190000.0 (changed N/A YoY) and the FY2018 annual result came in at $1.7 million, changed N/A from the prior year.
Total Debt was $190000.0 for Q3 2020 at Black Diamond Therapeutics, up from $15000.0 in the prior quarter.
Across five years, Total Debt topped out at $1.7 million in Q4 2018 and bottomed at $15000.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	110.96 Mn
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	959.06 Mn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	1.99 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Black Diamond Therapeutics	99.59 Mn	-18.67 Mn	-	-

Download Data